Related Experiment Video

Updated: Jun 2, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy

Daniela Masciocchi1, Arianna Gelain, Stefania Villa

  • 1Dipartimento di Scienze Farmaceutiche 'P. Pratesi', Università degli Studi di Milano, via L. Mangiagalli 25, 20133 Milano, Italy.

Future Medicinal Chemistry
|April 30, 2011
PubMed

Insights

This review evaluates promising inhibitors targeting Signal Transducer and Activator of Transcription 3 (STAT3) for cancer treatment. It explores their mechanisms, clinical development, and structure-activity relationships for effective anticancer drug discovery.

Area of Science:

  • Oncology
  • Molecular Biology
  • Medicinal Chemistry

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is a key oncogenic protein implicated in numerous cancers.
  • Aberrant STAT3 activity drives tumor development and progression, making it a critical therapeutic target.
  • Inhibiting STAT3 offers a validated strategy for cancer prevention and treatment.

Purpose of the Study:

  • To review and evaluate the most promising STAT3 inhibitors currently available.
  • To critically analyze the mechanisms of action for different classes of STAT3 inhibitors.
  • To consider the future clinical development prospects of these anticancer agents.

Main Methods:

  • Comprehensive literature review of validated therapeutic strategies targeting STAT3.
  • Classification of STAT3 inhibitors based on distinct mechanisms of action.
  • Analysis of structure-activity relationships and biological effects of inhibitors.
  • Evaluation of synthetic and technological advancements for drug development.

Main Results:

  • Identification and discussion of promising STAT3 inhibitors.
  • Detailed explanation of the mechanisms of action for various inhibitor classes.
  • Assessment of structure-activity relationships and biological impacts.
  • Overview of recent synthetic and technological approaches to overcome drug development challenges.

Conclusions:

  • STAT3 inhibition represents a promising therapeutic avenue for various cancers.
  • Understanding inhibitor mechanisms and structure-activity relationships is crucial for clinical success.
  • Ongoing synthetic and technological innovations are vital for developing clinically viable STAT3-targeting drugs.

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...